Hiremath 2006.

Methods	Design: randomised controlled trial following a baseline period of 2 to 4 weeks (rescue medication only) and an intervention period of 12 weeks Location and number of centres: not reported
Participants	Number screened: not reported Number randomised: 512 Number completed: not reported Age: children and adolescents (4 to 15 years) with predominantly moderate‐to‐severe asthma Gender: not reported Asthma severity: forced expiratory volume in 1 second (FEV1) 50‐90% of predicted Inclusion/exclusion criteria: not reported
Interventions	Ciclesonide 160 μg (ex‐actuator; N = 254) once daily in the evening Fluticasone 88 μg twice daily (176 μg/day, ex‐actuator; N = 258) Delivery: both medications were administered via a metered‐dose inhaler with spacer (AeroChamber Plus®) Inhalation technique: not reported Treatment period: 12 weeks (following 2 to 4 weeks' baseline period rescue medication only) Allowed asthma medication: not reported
Outcomes	FEV1 from baseline to the end of the treatment period, morning peak expiratory flow, median percentage of asthma symptom‐ and rescue medication‐free days and incidence of adverse events
Notes	Incomplete data since this study was only published as an abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) Outcomes 1, 3, 4, 5	Unclear risk	Not described
Blinding (performance bias and detection bias) Other outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) Outcomes 1, 3, 4, 5	Unclear risk	Not described
Incomplete outcome data (attrition bias) Other outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not enough information
Other bias	Unclear risk	Not enough information